Supraflex Cruz - Improving patient outcomes: from simple to complex patients

Sponsored by SMT

Anchorperson: P. Serruys

Spokesperson: F. Sharif

Summary

Discover the remarkable performance of Supraflex Cruz in real-world clinical settings, showcasing exceptionally low event rates and demonstrating its safety and efficacy across a spectrum of high-risk patients, including the elderly and those with high bleeding risks, and delve into the ongoing TALENT and TUDEXO II trials, designed to further elucidate the benefits of employing best PCI practices, particularly focusing on the efficacy of ultrathin struts such as Supraflex Cruz in managing complex CAD, including three-vessel disease, especially in diabetic populations.

Learning Objectives

To learn that the treatment spectrum of Supraflex Cruz DES encompasses both simple and complex coronary artery disease (CAD)
To learn the safety and efficiency of Supraflex Cruz across all patient strata (real world clinical practice; randomised control trials; elderly; high bleeding risk, diabetes)
To learn the optimal contemporary approach in PCI, encompassing (a) patient selection, (b) physiology to decide on revascularisation, (c) intravascular imaging to optimise PCI and (d) optimal medical therapy, within the ongoing trials addressing 3-vessel disease with and without diabetes mellitus